A5010781894- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Breast Lesions and Carcinomas
- Cancer Risks and Factors
- BRCA gene mutations in cancer
- Medical Imaging Techniques and Applications
- Cancer Diagnosis and Treatment
- Breast Implant and Reconstruction
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- MRI in cancer diagnosis
- Metastasis and carcinoma case studies
- Cancer survivorship and care
- Musculoskeletal pain and rehabilitation
- Ovarian function and disorders
- Nerve Injury and Rehabilitation
- Cancer-related cognitive impairment studies
- Digital Radiography and Breast Imaging
- Spine and Intervertebral Disc Pathology
- Head and Neck Cancer Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
Ewha Womans University
2021-2024
Ulsan College
2012-2021
University of Ulsan
2012-2021
Asan Medical Center
2012-2021
Male breast cancer (MBC) is a rare condition, and recent research has underscored notable distinctions between MBC in women. This study aimed to assess contrast the long-term survival outcomes disease patterns of patients with those their female counterparts.
Abstract We evaluated the prognostic implications of circulating tumor cell (CTC) count in non-metastatic, HER2-negative breast cancer patients who failed to achieve pathologic complete response (pCR) after neoadjuvant chemotherapy (NCT). A total 173, non-metastatic treated with NCT were prospectively enrolled. CTCs obtained from blood drawn pre-NCT and post-NCT using a SMART BIOPSY SYSTEM isolation kit (Cytogen Inc., Seoul, Korea) immunofluorescence staining. Excluding 26 HER2-positive...
The plasma proteome of 51 non-metastatic breast cancer patients receiving neoadjuvant chemotherapy (NCT) was prospectively analyzed by high-resolution mass spectrometry coupled with nano-flow liquid chromatography using blood drawn at the time diagnosis. Plasma proteins were identified as potential biomarkers, and their correlation clinicopathological variables survival outcomes analyzed. Of patients, 20 (39.2%) HR+/HER2-, five (9.8%) HR+/HER2+, HER2+, 21 (41.2%) triple-negative subtype....
Importance Young patients with breast cancer have higher risk for developing contralateral (CBC) and epidemiologic characteristics different from those of older patients. Objective To examine the incidence peak occurrence CBC according to age at primary (PBC) surgery. Design, Setting, Participants This cohort study included who were diagnosed underwent surgery unilateral nonmetastatic Asan Medical Center, Korea, between January 1, 1999, December 31, 2013, follow-up through 2018. Data...
Importance Contralateral breast cancer (CBC) is the most frequently diagnosed primary in patients with cancer. Although many studies have reported survival after development of CBC, results been inconsistent. Objective To investigate whether CBC associated among Design, Setting, and Participants This cohort study was conducted at Asan Medical Center, Korea, who were unilateral, nonmetastatic, stage 0 to III between 1999 2013 followed up through 2018. The median (IQR) follow-up 107 (75-143)...
Backgrounds/Aims Gallbladder carcinoma (GBCa) T2 lesions are considered to be advanced tumors showing diverse features in tumor extent. When this lesion does not involve the cystic duct and there is no evidence of lymph node metastasis, we have consider what most reasonable extent resection - that is, whether perform concurrent extra-hepatic bile (EHBD) or not. This study intends evaluate adequacy EHBD patients undergoing for T2N0 GBCa. Methods From our institutional database GBCa, 48 cases...
Purpose Restricted shoulder mobility is a major upper extremity dysfunction associated with lower quality of life and disability after breast cancer surgery. We hypothesized that poloxamer sodium alginate mixture (Guardix-SG®) applied axillary lymph node dissection (ALND) would significantly improve range motion (ROM) in patients cancer. Methods conducted double-blind, randomized, prospective study to evaluate the clinical efficacy safety Guardix-SG® for prevention ALND. The primary outcome...
In this study, we aimed to evaluate axillary lymph node dissection (ALND) rates and prognosis in neoadjuvant chemotherapy (NCT) compare with endocrine therapy (NET) estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), (LN)-positive, premenopausal breast cancer patients (NCT01622361). The multicenter, phase 3, randomized clinical trial enrolled 187 women from July 5, 2012, May 30, 2017. were randomly assigned (1:1) either 24 weeks of NCT including...
The extension of endocrine therapy beyond 5 years for recurrence-free survivors breast cancer improves survival; however, the issue on how to clinically identify appropriate candidates remains controversial. This study aimed prognostic factors breast-cancer-specific mortality in patients who have had tamoxifen treatment and categorize subgroups based risk death using combinations these assist clinical decision perform further therapy.In total, 3,158 with were enrolled. Breast cancer-specific...
Abstract Purpose: Metastatic/recurrent breast cancer has a relatively long survival compared to other cancers and depending on the biologic subtype, treatment outcome is different. In general, obesity or overweight associated with poor prognosis of cancer, but relationship between body mass index (BMI) in metastatic cases not clear. The aim this study investigating effect BMI through long-term follow-up single institution, retrospectively. Method: This included patients metastatic/recurrent...
Abstract Analysis of clinical benefit in the real world HER2-positive metastatic breast cancer following development anti-HER2 therapeutics over past 20 years Ahrong Ham1, Sewon Lee1, Jungmin Jo1, Soo Ji Hong2, Eun Lee2, Haena Sungchan Gwark2, Jeongshin An2, Hyun Goo Kim2, Jun Woo Joohyun Woo2, Woosung Lim2, Byung-In Moon2, Sei Ahn2, Hye Ah Lee3, Kyoung Lee1 1 Division Hematology and Oncology, Department Internal Medicine, Ewha Womans University Mokdong hospital, College Seoul, Republic...
Abstract Background: Young age is associated with poor prognosis and aggressive biology in early breast cancer, especially luminal subtypes. But the prognostic impact of metastatic cancer (MBC) unclear. Also it known that chemotherapy more effective estrogen receptor (ER)-negative tumors than ER-positive young patients respond better to chemotherapy. The authors tried evaluate on disease outcome according ER status. Methods: We collected individual patient data from January 2000 December...
Chemo-endocrine therapy can lead to various side effects associated with ovarian dysfunction. Predicting menstrual recovery is necessary discuss the treatment-related issues regarding fertility and premature menopause patients. In ASTRRA trial, patients who resumed function within 2 years after chemotherapy were randomized receive tamoxifen for 5 or OFS years. With these 1298 patients, we developed a model that predicts when will occur 3-year period using variables including age, body mass...
We aimed to evaluate the patient-reported outcomes (PROs) in a prospective phase III clinical trial, comparing neoadjuvant endocrine therapy (NET) with conventional chemotherapy (NCT) patients hormone status positive, lymph node-positive premenopausal breast cancer (NCT01622361). The were randomized prospectively either 24 weeks of NCT adriamycin plus cyclophosphamide followed by taxane or NET gonadotropin-releasing agonist and tamoxifen. examined at surgery unit large tertiary care hospital...
Abstract Background: Improved understanding of factors affecting the accuracy breast MRI after NST can lead to more tailored use in deciding surgical extent NST. Purpose: To investigate whether magnetic resonance imaging (MRI) and caliper predicting residual tumor is affected by neoadjuvant treatment estrogen receptor (ER) positive HER2-negative, lymph node-positive, premenopausal cancer cancer. Materials Methods: We analyzed clinicopathologic data 123 patients phase 3, randomized clinical...
Background: While the relationship between mammographic breast density reduction (MDR) and endocrine therapy efficacy has been reported in estrogen receptor-positive cancer, it is still unclear premenopausal women, especially case of adding ovarian function suppression (OFS) to anti-hormone therapy. We investigated impact MDR on prognosis stratified by treatment based updated results ASTRRA trial. Materials Methods: The trial, a randomized phase III study, showed that OFS tamoxifen (TAM)...
e12626 Background: We aimed to evaluate patient-reported outcomes (PROs) in the NEST phase III trial, which neoadjuvant endocrine therapy (NET) compared conventional chemotherapy (NCT) for hormone-responsive lymph node-positive premenopausal breast cancer. Methods: Premenopausal women with estrogen receptor (ER)-positive, HER2-negative, and cancer patients were enrolled. Patients randomized either 24 weeks of adriamycin plus cyclophosphamide (AC) followed by taxane (T) or zoladex tamoxifen....
e12531 Background: Neoadjuvant chemotherapy (NCT) in breast cancer has several advantages such as more conservation surgery (BCS) rate and de-escalation of extent axillary surgery. Actual practice change this area compared with adjuvant (ACT) is not well established. Methods: We retrospectively analyzed 5,141 women diagnosed from 2009 to 2013, treated before or after definite BCS categories (sentinel lymph node biopsy (SNB), lymphnode dissection (ALND) SNB followed by ALND) are between two...
e19242 Background: We aimed to evaluate patient-reported outcomes (PROs) in the NEST phase III trial, which neoadjuvant endocrine therapy (NET) compared conventional chemotherapy (NCT) for hormone-responsive lymph node-positive premenopausal breast cancer. Methods: Premenopausal women with estrogen receptor (ER)-positive, HER2-negative, and cancer patients were enrolled. Patients randomized either 24 weeks of doxorubicin plus cyclophosphamide followed by taxane (T) or goserelin tamoxifen....
An amendment to this paper has been published and can be accessed via a link at the top of paper.